MARKET

SPRB

SPRB

Spruce Biosciences, Inc.
NASDAQ
46.67
-2.68
-5.42%
Closed 19:30 11/10 EST
OPEN
48.96
PREV CLOSE
49.34
HIGH
48.96
LOW
44.74
VOLUME
72.52K
TURNOVER
517.71K
52 WEEK HIGH
129.00
52 WEEK LOW
38.06
MARKET CAP
134.12M
P/E (TTM)
-1.3179
1D
5D
1M
3M
1Y
5Y
1D
B. Riley Securities Sticks to Its Buy Rating for Spruce Biosciences (SPRB)
TipRanks · 20h ago
Oppenheimer Reaffirms Their Buy Rating on Spruce Biosciences (SPRB)
TipRanks · 21h ago
Spruce Biosciences Faces Funding Risk as Uncertainty Looms Over TA-ERT FDA Priority Review Voucher and Sale Prospects
TipRanks · 1d ago
Spruce Biosciences Q3 EPS $(8.51) Up From $(14.58) YoY
Benzinga · 1d ago
Spruce Biosciences GAAP EPS of -$8.51 misses by $2.83
Seeking Alpha · 1d ago
Spruce Biosciences reports Q3 EPS ($8.51), consensus ($5.51)
TipRanks · 1d ago
Spruce Biosciences sees cash runway into 2H27
TipRanks · 1d ago
Press Release: Spruce Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Dow Jones · 1d ago
More
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders with significant unmet medical need. It has a diverse portfolio of product candidates addressing diseases with high unmet medical need and clear biology for treatment, for which there are either no approved therapies treating the underlying disease or suboptimal treatment options. Its pipeline consists of TA-ERT, Tildacerfont and Cortibon, and SPR202. TA-ERT is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase. TA-ERT is intended as an enzyme replacement therapy for the treatment of patients with MPS IIIB who lack rhNAGLU enzyme activity. Tildacerfont has the potential to address hyperactive brain corticotropin-releasing factors neurotransmission and aberrant functioning of the hypothalamus-pituitary-adrenal axis in patients with MDD. SPR202 focuses on the treatment of Congenital Adrenal Hyperplasia and other indications.

Webull offers Spruce Biosciences, Inc stock information, including NASDAQ: SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.